Patents by Inventor Edouard C. Nice

Edouard C. Nice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
    Publication number: 20240117073
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 26, 2023
    Publication date: April 11, 2024
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard C. Nice, Anne Murray, George Mark
  • Method for stimulating proliferation of colon cells using POMC.sub.76-103
    Patent number: 5547940
    Abstract: The invention describes how known peptide POMC.sub.76-103 can be used to stimulate colon cell proliferation. The peptide can be used alone, or in combination with other cell proliferation stimulating agents.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: August 20, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Edouard C. Nice, Robert James, Richard J. Simpson, Antony W. Burgess, Robert H. Whitehead
  • Human leukemia inhibitory factor
    Patent number: 5443825
    Abstract: Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: August 22, 1995
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
  • Recombniant method for making leukemia inhibitor factor
    Patent number: 5427925
    Abstract: The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.
    Type: Grant
    Filed: May 6, 1993
    Date of Patent: June 27, 1995
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
  • Leukaemia inhibitory factor
    Patent number: 5187077
    Abstract: A leukaemia-inhibitory factor (LIF) is disclosed, together with a method of preparation of LIF in essentially pure form. Nucleotide and amino acid sequences are disclosed, together with recombinant DNA moleclues and host cells for production of polypeptides having LIF activity.
    Type: Grant
    Filed: December 9, 1988
    Date of Patent: February 16, 1993
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson